Literature DB >> 8781565

Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life.

M Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8781565     DOI： 10.1007/bf01213547

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  7 in total

1.  Neurotoxicity of cisplatin and taxol.

Authors:  E. Warner
Journal:  Int J Gynecol Cancer       Date:  1995-05       Impact factor: 3.437

2.  Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.

Authors:  E Connelly; M Markman; A Kennedy; K Webster; B Kulp; G Peterson; J Belinson
Journal:  Gynecol Oncol       Date:  1996-08       Impact factor: 5.482

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.

Authors:  J H Schiller; B Storer; K Tutsch; R Arzoomanian; D Alberti; C Feierabend; D Spriggs
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

Review 5.  Cisplatin-associated neurotoxicity: can it be prevented?

Authors:  D S Alberts; J K Noel
Journal:  Anticancer Drugs       Date:  1995-06       Impact factor: 2.248

6.  Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.

Authors:  V Chaudhry; E K Rowinsky; S E Sartorius; R C Donehower; D R Cornblath
Journal:  Ann Neurol       Date:  1994-03       Impact factor: 10.422

7.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245
  7 in total
  13 in total

Review 1.  Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review.

Authors:  Floortje Mols; Tonneke Beijers; Gerard Vreugdenhil; Lonneke van de Poll-Franse
Journal:  Support Care Cancer       Date:  2014-05-01       Impact factor: 3.603

2.  Neurocognitive and psychosocial outcomes in adult survivors of childhood soft-tissue sarcoma: A report from the St. Jude Lifetime Cohort.

Authors:  Ingrid Tonning Olsson; Tara M Brinkman; Mingjuan Wang; Matthew J Ehrhardt; Pia Banerjee; Daniel A Mulrooney; I-Chan Huang; Kirsten K Ness; Michael W Bishop; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull
Journal:  Cancer       Date:  2020-01-08       Impact factor: 6.860

3.  Sleep status of cervical cancer patients and predictors of poor sleep quality during adjuvant therapy.

Authors:  Jun Tian; Gui Lin Chen; Hai Rong Zhang
Journal:  Support Care Cancer       Date:  2014-11-05       Impact factor: 3.603

4.  Neurocognitive outcomes in long-term survivors of Wilms tumor: a report from the St. Jude Lifetime Cohort.

Authors:  Ingrid Tonning Olsson; Tara M Brinkman; Geehong Hyun; Pia Banerjee; Daniel A Mulrooney; I-Chan Huang; Daniel M Green; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull
Journal:  J Cancer Surviv       Date:  2019-06-26       Impact factor: 4.442

5.  The investigation of immunomodulatory activities of Gloeostereum incaratum polysaccharides in cyclophosphamide-induced immunosuppression mice.

Authors:  Di Wang; Qian Li; Yidi Qu; Mengya Wang; Lanzhou Li; Yang Liu; Yu Li
Journal:  Exp Ther Med       Date:  2018-01-30       Impact factor: 2.447

6.  The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients.

Authors:  J S Hong; J Tian; L H Wu
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

7.  Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure.

Authors:  C M L Driessen; K M E de Kleine-Bolt; A J J M Vingerhoets; F Mols; G Vreugdenhil
Journal:  Support Care Cancer       Date:  2011-12-09       Impact factor: 3.603

8.  Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology.

Authors:  Emily I Chen; Katherine D Crew; Meghna Trivedi; Danielle Awad; Mathew Maurer; Kevin Kalinsky; Antonius Koller; Purvi Patel; Jenny Kim Kim; Dawn L Hershman
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

9.  CXCR1/2 pathways in paclitaxel-induced neuropathic pain.

Authors:  Laura Brandolini; Elisabetta Benedetti; Pier Adelchi Ruffini; Roberto Russo; Loredana Cristiano; Andrea Antonosante; Michele d'Angelo; Vanessa Castelli; Antonio Giordano; Marcello Allegretti; Annamaria Cimini
Journal:  Oncotarget       Date:  2017-04-04

10.  Investigation on the immunomodulatory activities of Sarcodon imbricatus extracts in a cyclophosphamide (CTX)-induced immunosuppressanted mouse model.

Authors:  Fanxin Meng; Panju Xu; Xue Wang; Yu Huang; Liyan Wu; Yiling Chen; Lirong Teng; Di Wang
Journal:  Saudi Pharm J       Date:  2017-04-21       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.